United States - English - NLM (National Library of Medicine)

emd serono, inc. - follitropin (unii: 076whw89tw) (follitropin - unii:076whw89tw) - follitropin 450 [iu] in 1 ml - gonal-f is indicated for:       gonal-f is contraindicated in women and men who exhibit: - prior hypersensitivity to recombinant fsh products or one of their excipients. reactions have included anaphylaxis [see warning and precautions (5.1)] - high levels of fsh indicating primary gonadal failure - the presence of uncontrolled non-gonadal endocrinopathies (for example, thyroid, adrenal, or pituitary disorders) - sex hormone dependent tumors of the reproductive tract and accessory organs - tumors of pituitary gland or hypothalamus gonal-f is also contraindicated in women who exhibit: - abnormal uterine bleeding of undetermined origin - ovarian cyst or enlargement of undetermined origin risk summary gonal-f is not indicated in pregnant women the incidence of congenital malformations after some assisted reproductive technology, specifically in vitro fertilization (ivf) or intracytoplasmic sperm injection (icsi)], may be slightly higher than that after spontaneous conception. this slightly higher incidence is tho

United States - English - NLM (National Library of Medicine)

emd serono, inc. - follitropin (unii: 076whw89tw) (follitropin - unii:076whw89tw) - follitropin 75 [iu] in 1 ml - gonal-f rff is indicated for: gonal-f rff is contraindicated in women who exhibit: - prior hypersensitivity to recombinant fsh products or one of their excipients. reactions have included anaphylaxis [see warnings and precautions (5.1)]. - high levels of fsh indicating primary gonadal failure - the presence of uncontrolled non-gonadal endocrinopathies (for example, thyroid, adrenal, or pituitary disorders) - sex hormone dependent tumors of the reproductive tract and accessory organs - tumors of the pituitary gland or hypothalamus - abnormal uterine bleeding of undetermined origin - ovarian cyst or enlargement of undetermined origin risk summary gonal-f rff is not indicated in pregnant women. the incidence of congenital malformations after some assisted reproductive technology [(art), specifically in vitro fertilization (ivf) or intracytoplasmic sperm injection (icsi)], may be slightly higher than that after spontaneous conception. this slightly higher incidence is thought to be related to differences in par

Australia - English - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme (australia) pty ltd - corifollitropin alfa -

Israel - English - Ministry of Health

merck serono ltd - follitropin alfa - powder for solution for injection - follitropin alfa 5.5 mcg/dose - follitropin alfa - follitropin alfa - 1) gonal-f followed by chorionic gonadotrophin (hcg) is recommended for the stimulation of follicular development and ovulation in women with hypothalamic-pituitary dysfunction who present with either oligomenorrhoea or amenorrhoea. these women are classified as w.h.o group ii patients and usually receive clomiphene citrate as primary therapy. they have evidence of endogenous oestrogen production and thus will either spontaneously menstruate or experience withdrawal bleeding after progestagen administration. polycystic ovarian disease (pcod) is part of the who ii classification and is present in the majority of these patients. 2) gonal-f is indicated for stimulation of multifollicular development in patients undergoing superovulation for assisted reproductive technologies (art) such as in vitro fertillization (ivf) gamete intra-fallopian transfer (gift) and zogote intra-fallopian transfer (zift). 3) gonal-f is indicated with concomitant human chorionic gonadotrophin (hcg) therapy for the stimulation of spermatogenesis in men who have congenital or acquired hypogonadotrophic hypogonadism.

Israel - English - Ministry of Health

merck serono ltd - follitropin alfa; lutropin alfa - powder and solvent for solution for injection - follitropin alfa 150 iu; lutropin alfa 75 iu - follitropin alfa - follitropin alfa - pergoveris is indicated for the stimulation of follicular development in women with severe lh and fsh deficiency. in clinical trials, these patients were defined by an endogenous serum lh level < 1.2 iu/l.

Israel - English - Ministry of Health

organon pharma israel ltd., israel - follitropin beta - solution for injection - follitropin beta 833 iu / 1 ml - follitropin beta - follitropin beta - puregon is indicated for the treatment of female infertility in the following clinical situations: anovulation (including polycystic ovarian disease, pcod) in women who have beenunresponsive to treatment with clomiphene citrate. controlled ovarian hyperstimulation to induce the development of multiple follicles in medically assisted reproduction programs [ e.g. in vitro fertilisation/embryo transfer (ivf/et), gamete intra-fallopian transfer (gift) and intracytoplasmic sperm injection (icsi)]. in the male : deficient spermatogenesis due to hypogonadotrophic hypogonadism.

Australia - English - Department of Health (Therapeutic Goods Administration)

organon pharma pty ltd - follitropin beta, quantity: 833 iu/ml - injection, solution - excipient ingredients: sucrose; sodium citrate dihydrate; polysorbate 20; benzyl alcohol; methionine; hydrochloric acid; sodium hydroxide; water for injections - female: anovulatory infertility and; controlled ovarian hyperstimulation to induce the development of multiple follicles in medically assisted reproduction programs (e.g. in vitro fertilisation and related procedures). male: for the treatment of deficient spermatogenesis due to hypogonadotrophic hypogonadism.

United States - English - NLM (National Library of Medicine)

ferring pharmaceuticals inc. - follitropin (unii: 076whw89tw) (follitropin - unii:076whw89tw) - follitropin 75 [iu] in 1 ml

Israel - English - Ministry of Health

ferring pharmaceuticals ltd - follitropin delta - solution for injection - follitropin delta 12 mcg / 0.36 ml - follitropin delta - controlled ovarian stimulation for the development of multiple follicles in women undergoing assisted reproductive technologies (art) such as an in vitro fertilisation (ivf) or intracytoplasmic sperm injection (icsi) cycle. there is no clinical trial experience with rekovelle in the long gnrh agonist protocol

Israel - English - Ministry of Health

ferring pharmaceuticals ltd - follitropin delta - solution for injection - follitropin delta 36 mcg / 1.08 ml - follitropin delta - controlled ovarian stimulation for the development of multiple follicles in women undergoing assisted reproductive technologies (art) such as an in vitro fertilisation (ivf) or intracytoplasmic sperm injection (icsi) cycle. there is no clinical trial experience with rekovelle in the long gnrh agonist protocol